318 related articles for article (PubMed ID: 28608847)
1. HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model.
Toth K; Spencer JF; Ying B; Tollefson AE; Wold WSM
Viruses; 2017 Jun; 9(6):. PubMed ID: 28608847
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds.
Toth K; Tollefson AE; Spencer JF; Ying B; Wold WSM
Antiviral Res; 2017 Oct; 146():121-129. PubMed ID: 28827083
[TBL] [Abstract][Full Text] [Related]
3. Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.
Tollefson AE; Ying B; Spencer JF; Sagartz JE; Wold WSM; Toth K
J Virol; 2017 May; 91(10):. PubMed ID: 28250128
[TBL] [Abstract][Full Text] [Related]
4. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters.
Toth K; Ying B; Tollefson AE; Spencer JF; Balakrishnan L; Sagartz JE; Buller RM; Wold WS
Viruses; 2015 Mar; 7(3):1409-28. PubMed ID: 25807051
[TBL] [Abstract][Full Text] [Related]
5. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.
Ying B; Tollefson AE; Spencer JF; Balakrishnan L; Dewhurst S; Capella C; Buller RM; Toth K; Wold WS
Antimicrob Agents Chemother; 2014 Dec; 58(12):7171-81. PubMed ID: 25224011
[TBL] [Abstract][Full Text] [Related]
6. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.
Tollefson AE; Spencer JF; Ying B; Buller RM; Wold WS; Toth K
Antiviral Res; 2014 Dec; 112():38-46. PubMed ID: 25453340
[TBL] [Abstract][Full Text] [Related]
7. USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses.
Toth K; Spencer JF; Ying B; Tollefson AE; Hartline CB; Richard ET; Fan J; Lyu J; Kashemirov BA; Harteg C; Reyna D; Lipka E; Prichard MN; McKenna CE; Wold WSM
Antiviral Res; 2018 May; 153():1-9. PubMed ID: 29510156
[TBL] [Abstract][Full Text] [Related]
8. The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution.
Lugthart G; Oomen MA; Jol-van der Zijde CM; Ball LM; Bresters D; Kollen WJ; Smiers FJ; Vermont CL; Bredius RG; Schilham MW; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2015 Feb; 21(2):293-9. PubMed ID: 25464118
[TBL] [Abstract][Full Text] [Related]
9. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir.
Diaconu I; Cerullo V; Escutenaire S; Kanerva A; Bauerschmitz GJ; Hernandez-Alcoceba R; Pesonen S; Hemminki A
J Gene Med; 2010 May; 12(5):435-45. PubMed ID: 20440754
[TBL] [Abstract][Full Text] [Related]
10. In vitro co-infection by cytomegalovirus improves the antiviral activity of ganciclovir against human adenovirus.
Aguilar-Guisado M; Marrugal-Lorenzo JA; Berastegui-Cabrera J; Merino L; Pachón J; Sánchez-Céspedes J
Int J Antimicrob Agents; 2020 Aug; 56(2):106046. PubMed ID: 32540429
[TBL] [Abstract][Full Text] [Related]
11. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.
Romanowski EG; Yates KA; Gordon YJ
Antiviral Res; 2001 Dec; 52(3):275-80. PubMed ID: 11675144
[TBL] [Abstract][Full Text] [Related]
12. New drug on the horizon for treating adenovirus.
Wold WS; Toth K
Expert Opin Pharmacother; 2015; 16(14):2095-9. PubMed ID: 26330121
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid receptor β, a potential therapeutic target in the inhibition of adenovirus replication.
Wang X; Zhang Q; Zhou Z; Liu M; Chen Y; Li J; Xu L; Guo J; Li Q; Yang J; Wang S
Antiviral Res; 2018 Apr; 152():84-93. PubMed ID: 29421320
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy for adenovirus infections.
Lenaerts L; Naesens L
Antiviral Res; 2006 Sep; 71(2-3):172-80. PubMed ID: 16698093
[TBL] [Abstract][Full Text] [Related]
15. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir.
Kaneko H; Mori S; Suzuki O; Iida T; Shigeta S; Abe M; Ohno S; Aoki K; Suzutani T
Antiviral Res; 2004 Jan; 61(1):63-6. PubMed ID: 14670595
[TBL] [Abstract][Full Text] [Related]
16. Drug development against human adenoviruses and its advancement by Syrian hamster models.
Wold WSM; Tollefson AE; Ying B; Spencer JF; Toth K
FEMS Microbiol Rev; 2019 Jul; 43(4):380-388. PubMed ID: 30916746
[TBL] [Abstract][Full Text] [Related]
17. An adenovirus type F41 outbreak in a pediatric bone marrow transplant unit: analysis of clinical impact and preventive strategies.
Mattner F; Sykora KW; Meissner B; Heim A
Pediatr Infect Dis J; 2008 May; 27(5):419-24. PubMed ID: 18382384
[TBL] [Abstract][Full Text] [Related]
18. Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.
Voigt S; Hofmann J; Edelmann A; Sauerbrei A; Kühl JS
Transpl Infect Dis; 2016 Oct; 18(5):791-794. PubMed ID: 27482652
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.
Nwanegbo EC; Romanowski EG; Gordon YJ; Gambotto A
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4171-6. PubMed ID: 17724203
[TBL] [Abstract][Full Text] [Related]
20. Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient.
Carter BA; Karpen SJ; Quiros-Tejeira RE; Chang IF; Clark BS; Demmler GJ; Heslop HE; Scott JD; Seu P; Goss JA
Transplantation; 2002 Oct; 74(7):1050-2. PubMed ID: 12394854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
